<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02300259</url>
  </required_header>
  <id_info>
    <org_study_id>15523</org_study_id>
    <secondary_id>I7T-MC-RMAG</secondary_id>
    <nct_id>NCT02300259</nct_id>
  </id_info>
  <brief_title>A Study of LY2623091 in Healthy Participants</brief_title>
  <official_title>A Study to Determine the Effect of CYP3A Inhibition on the Pharmacokinetics of LY2623091 and the Effect of LY2623091 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first purpose of this study is to evaluate the effect of itraconazole (and possibly
      diltiazem) on the amount of LY2623091 in the blood stream and how long the body takes to get
      rid of it.

      The second purpose of the study is to evaluate the effect of LY2623091 on the amount of
      simvastatin (and possibly tadalafil) in the blood stream and how long the body takes to get
      rid of it.

      The safety and tolerability of LY2623091 when given with itraconazole, simvastatin and
      diltiazem or tadalafil will be evaluated.

      There will be three groups of participants in this study. Results from Groups 1 and 2 will be
      analyzed during the study to determine whether to enroll participants in Group 3 or 4. The
      study is expected to last up to 40 days from the first dose to follow-up (inclusive).
      Screening may occur up to 28 days prior to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY2623091 and Cytochrome (CYP) P450 Substrates</measure>
    <time_frame>Predose up to 20 days after drug administration in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY2623091 and Cytochrome (CYP) P450 Substrates</measure>
    <time_frame>Predose up to 20 days after drug administration in each period</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2623091 (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2623091 administered orally once on Day 1 of Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Itraconazole + LY2623091 (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg simvastatin administered orally once daily on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2623091 + Simvastatin (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil (Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil + LY2623091 (Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2623091 (Group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diltiazem + LY2623091 (Group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2623091</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2623091 (Group 1)</arm_group_label>
    <arm_group_label>Itraconazole + LY2623091 (Group 1)</arm_group_label>
    <arm_group_label>LY2623091 + Simvastatin (Group 2)</arm_group_label>
    <arm_group_label>Tadalafil + LY2623091 (Group 3)</arm_group_label>
    <arm_group_label>LY2623091 (Group 4)</arm_group_label>
    <arm_group_label>Diltiazem + LY2623091 (Group 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Itraconazole + LY2623091 (Group 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Simvastatin (Group 2)</arm_group_label>
    <arm_group_label>LY2623091 + Simvastatin (Group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Tadalafil (Group 3)</arm_group_label>
    <arm_group_label>Tadalafil + LY2623091 (Group 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Diltiazem + LY2623091 (Group 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants as determined by medical history, physical examination, clinical
             laboratory tests, and electrocardiograms (ECGs).

          -  Have a body mass index (BMI) between 18 and 32.0 kilograms per square meter (kg/m^2)
             inclusive, at screening

          -  Female participants must be of non-childbearing potential

        Exclusion Criteria:

          -  In the opinion of the investigator or sponsor, are unsuitable for inclusion in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1‐877‐CTLILLY (1‐877‐285‐4559) or 1‐317‐615‐4559 Mon ‐ Fri 9 AM ‐ 5 PM Eastern time (UTC/GMT ‐ 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

